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Transplante cardíaco em amiloidose primária
Heart transplantation in primary amyloidosis
Abstract
Cardiac amyloidosis is a disease that highly compromises
the survival expectancy after the beginning of the
symptomatic phase, usually with sudden death as the final
event. The aggression to other organs, although, can make
heart transplantation a disputable form of treatment taking
into consideration the shortage of organ donors. The aim is
to report the evolution with a survival of seven years after
heart transplantation and in fair condition of a patient with
amyloidosis. One year after the heart transplantation, the
patient was referred to renal transplantation also in
consequence of the disease aggression. The patient evolution
was favorable compared to three other patients also from our
service, who died early after the diagnosis. Even considering
the multi-systemic nature of amyloidosis, we can accept that
in selected patients the heart transplantation is justified,
taking into account the very ill prognosis of the disease.
Descriptors: Amyloidosis. Heart transplantation.
Cardiomyopathies/surgery.
Resumo
A amiloidose cardíaca é doença altamente limitante da
sobrevida, por morte súbita na maioria dos pacientes. Pela
agressão contra outros órgãos, particularmente rins e
sistema nervoso central, o transplante cardíaco tem sido
opção questionável, face à escassez de órgãos. O objetivo é
relatar a evolução, com sobrevivência de 7 anos, da paciente
após transplante cardíaco por amiloidose, em boas condições.
Um ano após o transplante cardíaco, houve indicação de
transplante renal, também pela agressão da doença. Esta
paciente contrasta com outros três pacientes de nosso serviço
que foram a óbito, ainda na fase de avaliação. Apesar de sua
natureza multisistêmica, a amiloidose cardíaca pode, em
pacientes selecionados, justificar o transplante cardíaco,
pela gravidade do seu potencial evolutivo após o início dos
sintomas.
Descritores: Amiloidose. Transplante de coração.
Cardiomiopatias/cirurgia.
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CASE REPORT
Patient, V.A.C., 49 years-old, was referred to our service,
presenting heart dysfunction   class III/IV (NYHA). The
Doppler-echocardiogram performed revealed, normal size
of the right and left ventricles; ejection fraction of the left
ventricle was 53%, with probable biventricular amyloidal
infiltration, including the ventricular septum, interfering with
the myocardial complacence, compatible with the amyloidal
deposit disease; important tricuspid insufficiency and
minimal pericardial effusion (Figure 1). This finding was
confirmed by cardiac magnetic resonance that evidenced
compromising of the biventricular systolic function
probably as a result of the deposit disease.
On August 3, 2001, it was performed a myocardial biopsy
that revealed cardiac amyloidosis. Due to the unfavorable
evolution, characteristic of the primary cardiac amyloidosis,
it was indicated the heart transplantation (Figures 2 and 3).
 After performing protocol for heart transplantation
(normal laboratory examination, negative criss-cross match,
pulmonary gradient of 6 mmHg), the patient was accepted
for the heart transplantation procedure. On August 31, 2001,
she suffered cardiopulmonary arrest, being performed the
cardiopulmonary resuscitation maneuvers (CPR)
successfully and given priority for heart transplantation.
INTRODUCTION
Amyloidosis in its systemic primary
form presents frequent cardiac
aggression, as well as attacking the
kidneys, liver, intestines and other
organs; and due to the myocardial
aggression, important limitation of
survival in our experience ; and in the
literature review is very meaningful [1,2].
Table 1. Cases with death in previous experience of the group
Case
1
2
3
Gender
M
M
F
Age (years)
54
47
55
Type
?
AL
AL
Death
Sudden
Sudden
Aggravation of symptoms.
Sudden
Time after inclusion
in the list(d)
1
53
97
Fig. 1 – Echocardiogram evidenced deposit disease (observe the
ventricular septum)
Pereira et al. [3], in a national issue, have already
pointed out the very high rate of mortality when the
diastolic cardiac insufficiency in its clinical form is
installed. Out of eight patients with cardiac amyloidosis
studied, six patients presented cardiac insufficiency, three
patients died in less than three months, which is in
accordance with our previous experience of three cases
in which all died prior to the cardiac transplantation, still
in the evaluation stage (Table 1).
Cardiac transplantation is considered today a method
of undeniable importance in the treatment of terminal cardiac
insufficiency, which faces, however, the lack of organ
availability, resulting in a decrease in the number of
operations in the First World countries. Due to violence
control measures and mainly of vehicular accident
prevention through increasingly more strict traffic laws in
the Western world, it is believed that a deficiency in the
amount of organs, especially of hearts, will be gradual in
the next few years. This fact makes relevant the selection
of receptors, having preference for cardiac transplantation
those patients that present a positive potential of evolution
[4-8]. It was included in the aforementioned literature the
simultaneous transplantation of heart and liver, also affected
by the disease, which could enhance the evolution
prognostic of amyloidosis.
The cardiac transplantation in patients holding systemic
amyloidosis is still an issue as a result of the systemic
characteristics of the disease and of the relative
unpredictability of its natural history, which could
compromise the long-term survival of the receptors and,
therefore, make the initial procedure innocuous. The positive
evolution of the present case, operated on September 24,
2001; and the excellent clinical evolution of the patient
particularly after a kidney transplantation performed on
April 8, 2002, allow us to evaluate that, in selected cases,
this could be a reasonable procedure.
Nevertheless, reports in literature reveal clearly the
possibility of recurrence of the disease, either in the heart
or other organs [7-9].
Likewise, it is also extremely important the caution in
the diagnostic, particularly for the exclusion of another type
of restrictive cardiomyopathy, which is the constrictive
pericarditis, especially in unusual manifestations [10].
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On September 24, 2001, it was performed orthotopic
heart transplantation, without intercurrences, however,
being kept under peritoneal dialysis between September 19
and November 16, 2001.
The immunosupression applied was oral cyclosporine
70 mg, every 12 hours, and mofetil micofenofate 500 mg,
every 12 hours, applying 1 g of metylprednisolone at the
end of the heart transplantation.
The myocardial biopsies performed on October 24,
November 9 and December 16, 2001 revealed zero degree.
The renal function kept progressively declining, being
confirmed by renal biopsy performed on October 31, 2001,
the presence of renal amyloidosis, being indicated for
transplantation by the nephrology group.
The evolution after the renal transplantation, which was
performed on April 8, 2002; was positive when the
immunosupression threefold scheme was applied, adding
prednisone in low doses of 0.1 mg/kg to cyclosporine and
to mofetil micofenolate.
Fig. 2 - Endomyocardic Biopsy displaying amyloidosis
Fig. 3 - Endomyocardic Biopsy displaying amyloidosis
After 11 months from the cardiac transplantation, the
patient was interned due to tachycardia and fever to be
confirmed. It was performed a Doppler-echocardiogram that
revealed left ventricle with normal function, size and
segment contraction, mild tricuspid insufficiency, normal
aorta and right chambers, with no further abnormalities.
The cardiac biopsy demonstrated zero degree, eliminating
rejection from the graft, maintaining the same scheme of
immunosupression.
It was diagnosed bronchopneumonia by the thorax X-
Ray and clinical examination, being performed the adequate
therapy.
No biopsy performed revealed any evidence of
amyloidosis that could imply aggression rejection to the
implanted organ (Figure 4).
Fig. 4 – Endomyocardic Biopsy with 5 year - evolution, displaying
absence of infiltrated  amyloid
DISCUSSION
In the literature review, there is an insufficiency of series
with a significant number of cases that could establish a
reliable pattern for the dubious and difficult referral of
transplantation for cardiac amyloidosis. The larger series
found was at the Harefield Hospital, England, in which, out
of 10 operated cases, only one patient achieved late survival
[9]. All other issues on the subject refer to isolate cases,
however, there are reports that state the possibility of
treatment for the amyloidosis disease as a real clinical
alternative, which brings new expectations for these
patients [1,3-8].
In the present case there was also found renal
aggravation and we were able to preserve the kidneys
function at acceptable levels, reducing the cyclosporine
dosage. Nearly a year later, a renal transplantation was
required; however, it is worth mentioning the fact that no
cardiac biopsy suggested any degree of cardiac rejection,
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even considering the immunosupresor scheme attenuated
by the difficult clinical characteristics that the patient
presented.
Other three cases of cardiac amyloidosis evaluated at
our service, died right after the diagnosis, still at the stage
of diagnostic investigation for heart transplantation.
In the literature, we find different opinions regarding
the opportunity for heart transplantation as a consequence
of cardiac amyloidosis, however, due to the fair 4-year
evolution of our patient, we could assume that young
patients suffering limited amyloidosis aggression to the
heart (or heart and kidneys) can be candidates for heart
transplantation until there are larger series of patients that
could definitely clarify this difficult issue.
Also, favorable to this policy, there is the fact that the
clinical therapy for this deposit disease has been attempted
with reasonably initial success [2,6,9].
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